Indinavir

FDA label

Read the full label on DailyMed ↗

Renal Undefined

Hepatic Mild-to-moderate insufficiency due to cirrhosis: reduce to 600 mg q8h; severe not studied

Must be taken at 8-hour intervals; interrupt 1–3 days for nephrolithiasis/urolithiasis

Instructions

• Take without food, with water, 1 h before or 2 h after a meal (or with a light low-fat meal/other liquids)
• Drink at least 1.5 L of fluids per 24 h to maintain hydration
• Separate from didanosine by ≥1 h on an empty stomach

Available strengths

• cap 400 mg

Contraindications

• Coadministration with drugs whose CYP3A4-mediated metabolism indinavir inhibits, causing elevated levels with potentially serious or life-threatening reactions: alfuzosin; amiodarone; ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine); cisapride; lovastatin, simvastatin; pimozide; sildenafil for pulmonary arterial hypertension (Revatio); oral midazolam; triazolam; alprazolam

Cautions

• Nephrolithiasis/urolithiasis — maintain hydration
• Asymptomatic hyperbilirubinemia (indirect)
• Hepatitis/hepatic failure
• New-onset or worsening diabetes, hyperglycemia
• Hemolytic anemia
• Fat redistribution
• Increased spontaneous bleeding in hemophilia

Adverse reactions

• Nephrolithiasis/urolithiasis (flank pain, hematuria)
• Asymptomatic hyperbilirubinemia
• Nausea
• Abdominal pain
• Vomiting
• Headache
• Diarrhea

Pregnancy Optimal dosing not established; markedly reduced plasma levels during pregnancy

Lactation Undefined